Literature DB >> 20980835

Identification of a high affinity TAG-72 binding peptide by phage display selection.

Nan Xiao1, Dengfeng Cheng, Yi Wang, Ling Chen, Xinrong Liu, Shuping Dou, Guozheng Liu, Minmin Liang, Donald J Hnatowich, Mary Rusckowski.   

Abstract

PURPOSE: Phage display was used to select novel peptides that specifically bind the TAG-72 antigen and with properties suitable for imaging TAG-72 positive cancers.
RESULTS: After three rounds of selection against TAG-72 and using two different elution conditions including a long elution, the consensus sequences FRERCDKHPQKCTKFL and DPRHCQKRVLPCPAWL were expressed on phages G3-15 and T3-15 respectively. ELISA, fluorescence-activated cell sorting analysis and fluorescence microscopy provided evidence that both phages specifically bound TAG-72 in vitro. Both peptides are stable in 37oC serum. By a cell binding competition assay, the IC50 for T3-15 was measured as 0.29 nM and therefore 36-fold higher affinity than G3-15 at 10.32 nM. The biodistribution in mice carrying LS-174T tumors in one thigh were similar for both 99mTc-peptides at 30 min, but at 90 min the 99mTc-T3-15 peptide accumulated almost three times higher in the tumor. The SPECT/CT images were consistent with the biodistribution results. PROCEDURES: The f88-4/Cys6 phage library and two different elution conditions were used to identify two new higher affinity binding peptides for the TAG-72 antigen. One, was a single brief elution with pH 2.2 glycine buffer, and the second began with the glycine elution but was followed with a longer elution with Tris buffered saline (TBS) at pH 7.4. The phages that bound TAG-72 were evaluated by fluorescence-activated cell sorting analysis using TAG-72 positive LS-174T cells and confirmed by immunofluorescence imaging. The consensus peptides displayed on the selected phages were synthesized and conjugated with NHS-MAG3 for radiolabeling with 99mTc. The IC50 for TAG-72 binding was evaluated by cell binding competition in vitro while binding affinity was evaluated in vivo by necropsy and SPECT/CT imaging in a tumor mouse model.
CONCLUSION: We have identified a peptide with a sub nanomolar inhibition constant for the TAG-72 antigen that may have application in cancer imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20980835      PMCID: PMC3047098          DOI: 10.4161/cbt.11.1.13797

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  26 in total

1.  Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines.

Authors:  J B Ridgway; E Ng; J A Kern; J Lee; J Brush; A Goddard; P Carter
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

Review 2.  Quo vadis radioimmune imaging.

Authors:  A J Fischman; B A Khaw; H W Strauss
Journal:  J Nucl Med       Date:  1989-11       Impact factor: 10.057

3.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.

Authors:  D Stramignoni; R Bowen; B F Atkinson; J Schlom
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

4.  Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies.

Authors:  M J Losman; R L DeJager; M Monestier; R M Sharkey; D M Goldenberg
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

5.  Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.

Authors:  Cecile Desjobert; Vaea Richard de Soultrait; Aurelie Faure; Vincent Parissi; Simon Litvak; Laura Tarrago-Litvak; Michel Fournier
Journal:  Biochemistry       Date:  2004-10-19       Impact factor: 3.162

6.  Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Authors:  S V Kashmiri; L Shu; E A Padlan; D E Milenic; J Schlom; P H Hand
Journal:  Hybridoma       Date:  1995-10

7.  An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with (99m)Tc at room temperature.

Authors:  Yi Wang; Xinrong Liu; Donald J Hnatowich
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

8.  Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.

Authors:  C R Divgi; A M Scott; S Gulec; E K Broussard; N Levy; C Young; P Capitelli; F Daghighian; J M Williams; R D Finn
Journal:  Clin Cancer Res       Date:  1995-12       Impact factor: 12.531

9.  A new TAG-72 cancer marker peptide identified by phage display.

Authors:  Ling Chen; Yi Wang; Xinrong Liu; Shuping Dou; Guozheng Liu; Donald J Hnatowich; Mary Rusckowski
Journal:  Cancer Lett       Date:  2008-08-23       Impact factor: 8.679

10.  Identification and evaluation of a new tumor cell-binding peptide, FROP-1.

Authors:  Sabine Zitzmann; Susanne Krämer; Walter Mier; Ulrike Hebling; Annette Altmann; Axel Rother; Dietmar Berndorff; Michael Eisenhut; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  4 in total

Review 1.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

Review 2.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

Review 3.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

4.  Cancer cell-specific oligopeptides selected by an integrated microfluidic system from a phage display library for ovarian cancer diagnosis.

Authors:  Chih-Hung Wang; Chen-Hsun Weng; Yu-Jui Che; Kuan Wang; Gwo-Bin Lee
Journal:  Theranostics       Date:  2015-02-05       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.